Education
About Us
Working with TipRanks
Follow Us
Artelo Biosciences (ARTL)
:ARTL
ARTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $1.60
Previous CloseN/A
Volume8.82K
Average Volume (3M)17.13K
Market Cap
$2.81M
Enterprise Value-$1.13M
Total Cash (Recent Filing)$14.23K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding3,281,032
10 Day Avg. Volume13,101
30 Day Avg. Volume17,127
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$5.00Price Target Upside443.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Artelo Biosciences News
PremiumCompany Announcements
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
Artelo Biosciences Reports Q3 2024 Financials and Progress---
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.
Drug EfficacyART27.13 has shown significant weight gain in studies with no dose-limiting or fatal adverse events, indicating a promising safety profile.
Bears Say
Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.
Regulatory ChallengesRisks include failure of clinical trials, regulatory hurdles, commercialization challenges, and potential need for additional funding.
---
Ownership Overview
1.73%
Insiders
0.51%
Mutual Funds
<0.01% Other Institutional Investors
97.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ARTL FAQ
What was Artelo Biosciences’s price range in the past 12 months?
Artelo Biosciences lowest stock price was $0.85 and its highest was $1.60 in the past 12 months.
What is Artelo Biosciences’s market cap?
Artelo Biosciences’s market cap is $2.81M.
When is Artelo Biosciences’s upcoming earnings report date?
Artelo Biosciences’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Artelo Biosciences’s earnings last quarter?
Artelo Biosciences released its earnings results on Mar 03, 2025. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of -$0.437 by -$0.733.
Is Artelo Biosciences overvalued?
According to Wall Street analysts Artelo Biosciences’s price is currently Undervalued.
Does Artelo Biosciences pay dividends?
Artelo Biosciences does not currently pay dividends.
What is Artelo Biosciences’s EPS estimate?
Artelo Biosciences’s EPS estimate is -0.13.
How many shares outstanding does Artelo Biosciences have?
Artelo Biosciences has 3,281,032 shares outstanding.
What happened to Artelo Biosciences’s price movement after its last earnings report?
Artelo Biosciences reported an EPS of -$1.17 in its last earnings report, missing expectations of -$0.437. Following the earnings report the stock price went down -6.542%.
Which hedge fund is a major shareholder of Artelo Biosciences?
Currently, no hedge funds are holding shares in ARTL
---
Company Description
Artelo Biosciences
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
---
ARTL Stock 12 Month Forecast
Average Price Target
$5.00
▲(443.48% Upside)
Technical Analysis
Best Analysts Covering ARTL
1 Year
1 Year Success Rate
0/18 ratings generated profit
1 Year Average Return
-39.48%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.48% per trade.
---